HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).

Abstract
Hairy cell leukemia is a rare lymphoproliferative disorder resistant to conventional chemotherapeutic agents. Recently, the purine analogue cladribine (2-chlorodeoxyadenosine, 2-CdA) was introduced for the treatment of this disease. We report on 14 patients with hairy cell leukemia who were treated with 2-CdA at our department between 1993 and 1997. The patients received a single cycle of 2-CdA at a dose of 0.07 or 0.09 mg/kg/day by continuous infusion, over a seven-day period. Five patients were previously untreated, while the others had received prior treatment with interferon-alpha (seven patients), interferon-alpha and splenectomy (one patient) or interferon-alpha, splenectomy and pentostatin (one patient). Six patients achieved complete remission, three a good partial response and three partial remission. Two patients did not respond to treatment and one of them died from septicemia in aplasia. Relapse of the disease occurred in two patients. Side effects such as fever (WHO grade 2) and/or neutropenia (WHO grade 4) were noted in eight patients. Thus, 2-CdA is an effective treatment of hairy cell leukemia that can induce long lasting remissions in both, previously treated and untreated patients.
AuthorsW Füreder, A Weltermann, A Chott, H Gisslinger, P Valent, U Jäger, K Geissler, K Lechner
JournalWiener klinische Wochenschrift (Wien Klin Wochenschr) Vol. 111 Issue 24 Pg. 1027-30 (Dec 23 1999) ISSN: 0043-5325 [Print] Austria
PMID10677889 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Interferon-alpha
  • Pentostatin
  • Cladribine
Topics
  • Adult
  • Antibiotics, Antineoplastic (therapeutic use)
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Cladribine (administration & dosage, adverse effects, therapeutic use)
  • Data Interpretation, Statistical
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Interferon-alpha (therapeutic use)
  • Leukemia, Hairy Cell (drug therapy, mortality, therapy)
  • Male
  • Middle Aged
  • Pentostatin (therapeutic use)
  • Recurrence
  • Remission Induction
  • Splenectomy
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: